Seroprevalence of novel coronavirus disease (COVID-19) in Kobe, Japan
Seroprevalence of novel coronavirus disease (COVID-19) in Kobe, Japan
Abstract BackgroundCoronavirus disease 2019 (COVID-19) pandemic caused by SARS-CoV-2 has been affecting many people on earth and our society. Japan is known to have relatively less number of infections as well as deaths among developed nations. However, accurate prevalence of COVID-19 in Japan remains unknown. Therefore, we conducted a cross-sectional study to estimate seroprevalence of SARS-CoV-2 infection. MethodsWe conducted a cross-sectional serologic testing for SARS-CoV-2 antibody using 1,000 samples from patients at outpatient settings who visited the clinic from March 31 to April 7, 2020, stratified by the decade of age and sex. ResultsThere were 33 positive IgG among 1,000 serum samples (3.3%, 95%CI: 2.3-4.6%). By applying this figure to the census of Kobe City (population: 1,518,870), it is estimated that the number of people with positive IgG be 50,123 (95%CI: 34,934-69,868). Age and sex adjusted prevalence of positivity was calculated 2.7% (95%CI: 1.8-3.9%), and the estimated number of people with positive IgG was 40,999 (95%CI: 27,333-59,221). These numbers were 396 to 858 fold more than confirmed cases with PCR testing in Kobe City. ConclusionsOur cross-sectional serological study suggests that the number of people with seropositive for SARS-CoV-2 infection in Kobe, Japan is far more than the confirmed cases by PCR testing.
Doi Asako、Iwata Kentaro、Kuroda Hirokazu、Morimoto Takeshi、Nishioka Hiroaki、Hasuike Toshikazu、Nasu Seiko、Kihara Yasuki、Kanda Aya、Tomii Keisuke、Nagao Tomomi
Department of Infection Control, Kobe City Medical Center General Hospital||Department of Infectious Diseases, Kobe City Medical Center General Hospital||Division of Infectious Diseases Therapeutics, Kobe University Graduate School of MedicineDivision of Infectious Diseases Therapeutics, Kobe University Graduate School of MedicineDepartment of Infection Control, Kobe City Medical Center General Hospital||Department of Infectious Diseases, Kobe City Medical Center General HospitalDepartment of Clinical Epidemiology, Hyogo Medical CollegeDepartment of Infectious Diseases, Kobe City Medical Center General HospitalDepartment of Infection Control, Kobe City Medical Center General Hospital||Department of Infectious Diseases, Kobe City Medical Center General HospitalDepartment of Infection Control, Kobe City Medical Center General Hospital||Department of Laboratory Medicine, Kobe City Medical Center General HospitalKobe City Medical Center General HospitalDepartment of Laboratory Medicine, Kobe City Medical Center General HospitalDepartment of Respiratory Medicine, Kobe City Medical Center General HospitalDepartment of Laboratory Medicine, Kobe City Medical Center General Hospital
医学研究方法预防医学医药卫生理论
Doi Asako,Iwata Kentaro,Kuroda Hirokazu,Morimoto Takeshi,Nishioka Hiroaki,Hasuike Toshikazu,Nasu Seiko,Kihara Yasuki,Kanda Aya,Tomii Keisuke,Nagao Tomomi.Seroprevalence of novel coronavirus disease (COVID-19) in Kobe, Japan[EB/OL].(2025-03-28)[2025-05-10].https://www.medrxiv.org/content/10.1101/2020.04.26.20079822.点此复制
评论